Konstanze Hurth

This inventor holds 27 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Neurological Disorders. Top assignee: Novartis Ag. Active years: 2005-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Konstanze Hurth. Retrieved from https://idiyas.com/inventor/konstanze-hurth

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 27 (Patent Applications = 6)

% Patents Active = 74.1

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 5.2

ph-index = 8

Forward Citations = 182(Granted Patents)

Location History:

Loerrach, DE (2014)
Saint Louis, FR (2005 - 2017)
Lorrach, DE (2014 - 2020)

Company Filing History:

27 out of 3,978

Novartis Ag

patents

Years Active: 2005-2020

Loading Chart...

Areas of Expertise:

Heterocyclic Derivatives

Alpha7-nAChR Agonists

Cholinergic Ligands

Psychotic Disorders

Neurodegenerative Disorders

Organic Compounds

Quinazolin Derivatives

Piperidine Derivatives

CNS Diseases

Dihydro-Oxazine Derivatives

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10683287 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2020-06-16),

2. 10301296 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2019-05-28),

3. 10035794 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2018-07-31),

4. 9849117 - Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists (2017-12-26),

5. 9840498 - Substituted quinazolin-4-one derivatives (2017-12-12),

6. 9763952 - Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives (2017-09-19),

7. 9657010 - Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators (2017-05-23),

8. 9567343 - Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists (2017-02-14),

9. 9550758 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2017-01-24),

10. 9539260 - Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives (2017-01-10),

11. 9475811 - 1-aza-bicyclo[3.3.1]nonanes (2016-10-25),

12. 9284284 - Oxazine derivatives and their use in the treatment of disease (2016-03-15),

13. 9206181 - 1-aza-bicyclo[3.3.1] non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders (2015-12-08),

14. 9012451 - Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists (2015-04-21),

15. 8933090 - 1-aza-bicyclo[3.3.1]nonanes (2015-01-13),

Title: Konstanze Hurth - Pioneering Female Inventor from Saint Louis, FR

Introduction: Konstanze Hurth is a trailblazing inventor hailing from Saint Louis, FR, known for her groundbreaking contributions to the field of technology and innovation.

Latest Patents: Konstanze Hurth holds several patents in the areas of artificial intelligence, renewable energy, and sustainable transportation, showcasing her versatility and forward-thinking approach to invention.

Career Highlights: With a career spanning over two decades, Konstanze Hurth has worked with leading tech companies and research institutions, spearheading projects that have revolutionized the industry. Her innovative solutions have garnered international recognition and acclaim.

Collaborations: Throughout her career, Konstanze Hurth has collaborated with top engineers, scientists, and designers, fostering a culture of creativity and excellence. Her ability to work across disciplines has led to the development of cutting-edge technologies with real-world applications.

Conclusion: Konstanze Hurth's passion for innovation and dedication to pushing the boundaries of what is possible make her a true pioneer in the world of invention. Her work continues to inspire future generations of inventors and serves as a testament to the power of creativity and perseverance in driving positive change.

Profile summary based on public USPTO records.